The Lovenox reimbursement does not involve a formal liability; rather, the reimbursement is effectuated as a partial offset to MNTA’s net profits from the NVS-MNTA Lovenox collaboration, and this offset will already have been deducted to arrive at the number in the revenue line on MNTA’s income statement.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”